In addition, cfDNA has been used to detect EGFR mutations (exon 19 deletion or exon 21 (L858R) mutations) in selecting NSCLC cancer patients who may benefit from treatment with EGFR-TKIs and in identifying drug resistance mutations in lung cancer patients (11, 136–143). Here, EGFR is linked to non-small cell lung carcinoma.